Patients with advanced skin cancer can be rapidly tracked to participate in the “revolutionary” test of a new cancer vaccine.

The needle-free injection promotes the response of the immune system and it helps attack and helps identify cancer cells to prevent the disease.

Being coordinated by test Southempton clinical trial unitWhich is based in the university of the city, and aiming to expand the number of patients capable of participating.

Melanoma is the fifth most common cancer in the UK and about 4% in all new cancer cases, but research suggests that it is growing.

The NHS will work with the Oxford-based life science company Skansell, which will be determined to reference to patients in May at seven sites across England in Southampton.

Work is being done as part of NHS Cancer vaccine launch pad (CVLP)A test to help them find treatment for patients on their nearest participating NHS site.

63-year-old Dada-Char Paul Thomas of New Milton, Hampshire was first diagnosed with advanced skin cancer in 2017 and the disease continued to return after treatment.

He was put in a trial in July and said he felt lucky that he was involved in it.

“Thankfully I was still quite fit and ever since I went to it, my tumors all shrunk. Every time I go for a scan, they look shrinking, which is very exciting,” said Mr. Thomas.

“I am really expecting the total elimination of my cancer, as is exempted and I feel optimistic.”

Potential participants first require blood tests to determine their tissue type. It looks at the genes that control how the immune system works from a person to another.

Prof. Geth Griffiths, director of the Southampton Clinical Trial Unit, said: “We hope that being part of this ground-breaking program can help increase the referral for this test and give more patients with advanced melanoma access to new, potential life-safety treatments.”

You can follow BBC Hampshire and Isle of White But Facebook, XOr Instagram,